Marco Exams automatically processes endoscopic biopsies, IHC for HER2/PD-L1 and histologic evaluation results in Esophageal Cancer to generate differential diagnoses, prognostic stratification and therapeutic suggestions. The system transforms laboratory and pathology reports into structured, evidence-based clinical recommendations.
Some answers to questions we often receive
Marco Exams integrates endoscopic biopsies, IHC for HER2/PD-L1 and histologic evaluation results for Esophageal Cancer, including immunohistochemistry, FISH, next-generation sequencing (NGS), liquid biopsy (ctDNA) and imaging results when available in structured format, generating integrated clinical interpretation of all results.
Yes. Marco Exams connects via standard APIs (HL7 FHIR, ASTM) with leading LIS and LIMS systems. The integration allows Esophageal Cancer exam reports to flow automatically into Marco Exams, generating real-time clinical interpretation without manual intervention.
Yes. Marco Exams identifies Esophageal Cancer result patterns requiring urgent clinical action — an acquired resistance mutation, a molecular result indicating ineligibility for a planned therapy, or an unexpected actionable alteration — and generates directed alerts to the treating physician.
Marco Exams has an interpretation engine trained on Esophageal Cancer-specific biomarkers: HER2 IHC/FISH, PD-L1 CPS, MSI and histologic subtype. For each marker, the system knows positivity thresholds per international guidelines, current therapeutic implications and complementary testing recommendations when results are borderline or unexpected.
Marco Exams' evidence engine updates continuously with reference guidelines for Esophageal Cancer and published clinical trial data. FDA and EMA approvals and NCCN/ESMO guideline changes are systematically incorporated into the interpretation engine.
Marco Exams generates structured reports in PDF or web format, designed for direct presentation at Esophageal Cancer tumor boards. The report integrates all patient exam results, clinical interpretation, prognostic stratification and recommended therapeutic options with their evidence sources.
Esophageal biopsy reports do not automatically differentiate therapeutic implications between adenocarcinoma and squamous cell nor activate HER2/PD-L1 testing.